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ABSTRACT The MtrC-MtrD-MtrE multidrug efﬂux pump of Neisseria gonorrhoeae confers resistance to a diverse array of antimi-
crobialagentsbytransportingthesetoxiccompoundsoutofthegonococcus.Frequentlyingonococcalstrains,theexpressionof
themtrCDEoperonisdifferentiallyregulatedbybotharepressor,MtrR,andanactivator,MtrA.The mtrRgenelies250bpup-
streamofandistranscribeddivergentlyfromthe mtrCDEoperon.Previousresearchhasshownthatmutationsinthe mtrRcod-
ing region and in the mtrR-mtrCDE intergenic region increase levels of gonococcal antibiotic resistance and in vivo ﬁtness. Re-
cently,aC-to-Ttransitionmutation120bpupstreamofthe mtrCstartcodon,termedmtr120,wasidentiﬁedinstrainMS11and
showntobesufﬁcienttoconferhighlevelsofantimicrobialresistancewhenintroducedintostrainFA19.Herewereportthat
thismutationresultsinaconsensus 10elementandthatitspresencegeneratesanovelpromoterfor mtrCDEtranscription.
Thisnewlygeneratedpromoterwasfoundtobestrongerthanthewild-typepromoteranddoesnotappeartobesubjecttoMtrR
repressionorMtrAactivation.Althoughrare,the mtr120mutationwasidentiﬁedinanadditionalclinicalisolateduringsequence
analysisofantibiotic-resistantstrainsculturedfrompatientswithgonococcalinfections.Weproposethat cis-actingmutations
candevelopingonococcithatsigniﬁcantlyaltertheregulationofthe mtrCDEoperonandresultinincreasedresistancetoanti-
microbials.
IMPORTANCE Gonorrheaisthesecondmostprevalentsexuallytransmittedbacterialinfectionandaworldwidepublichealth
concern. As there is currently no vaccine against Neisseria gonorrhoeae, appropriate diagnostics and subsequent antibiotic ther-
apyremaintheprimarymeansofinfectioncontrol.However,theeffectivenessofantibiotictreatmentisconstantlychallenged
bytheemergenceofresistantstrains,mandatingathoroughunderstandingofresistancemechanismstoaidinthedevelopment
ofnewantimicrobialtherapiesandgeneticmethodsforantimicrobialresistancetesting.Thisstudywasundertakentocharac-
terizeanovelmechanismofantibioticresistanceregulationin N.gonorrhoeae.Hereweshowthatasinglebasepairmutation
generatesasecond,strongerpromoterfor mtrCDEtranscriptionthatactsindependentlyoftheknownefﬂuxsystemregulators
andresultsinhigh-levelantimicrobialresistance.
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N
eisseria gonorrhoeae, the causative agent of the sexually trans-
mitted infection gonorrhea, is a Gram-negative diplococcus
and is strictly a human pathogen. Clinical isolates of N. gonor-
rhoeae frequently exhibit high levels of antimicrobial resistance
mediated by multiple mechanisms, including active efﬂux of an-
timicrobialsbyfourknownefﬂuxpumps(1–5).TheMtrC-MtrD-
MtrE efﬂux pump is a well-characterized system that recognizes
andexportsawidevarietyofantimicrobialagents,includingmac-
rolide and -lactam antibiotics, detergents, and host antimicro-
bial factors (1, 6). Transcription of the mtrCDE operon is differ-
entially regulated by a repressor, MtrR, and an activator, MtrA
(7–9). The mtrR gene is located 250 bp upstream of and is tran-
scribed divergently from mtrCDE (3). MtrR represses the expres-
sion of mtrCDE via binding of two homodimers to pseudodirect
repeats within the mtrCDE promoter (10); the MtrR helix-turn-
helix(HTH)DNA-bindingmotifresidesbetweenresidues32and
53 (7, 11).
AvarietyofmutationsinmtrRandinthemtrR-mtrCDEinter-
genic region have been identiﬁed in antibiotic-resistant gonococ-
cal strains recovered from outbreak investigations (12). Strain
MS11, originally isolated in the 1960s from a patient with an un-
complicated cervical infection (13) and since used extensively by
many researchers, exhibits higher levels of intrinsic in vitro resis-
tance to MtrC-MtrD-MtrE substrates than do other laboratory
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MS11isanaturalmtrmutant,containinganalanine-to-threonine
substitution at position 39 in the MtrR DNA-binding domain, as
well as a novel C-to-T transition mutation located 120 bp up-
stream of the mtrC start codon (mtr120) (12). Introduction of the
mtr120 mutation into laboratory strain FA19 yielded one of the
highest reported levels of MtrC-MtrD-MtrE-based antimicrobial
resistance(12).Additionally,thismutationincreasedresistanceto
the host-derived antimicrobial compounds progesterone and
CRAMP-38, the murine homologue of the human cathelicidin
LL-37,suggestingthatthemtr120mutationfacilitatesresistanceto
hostdefensemechanisms(12).Inagreementwiththishypothesis,
the mtr120 mutation increased in vivo ﬁtness in a female mouse
modeloflowergenitaltractinfectionbynearly3logscomparedto
wild-typestrainFA19duringcompetitiveinfectionintheabsence
of antibiotic treatment (12).
Here we demonstrate that the mechanism of mtr120-based an-
timicrobial resistance is the generation of a consensus 10 ele-
ment (14) that acts as a second, stronger promoter for mtrCDE
transcription, resulting in substantially increased pump expres-
sion and enhanced resistance to antimicrobials. This promoter
appears to function independently of MtrR and MtrA regulation.
Additionally, we report that while the mtr120 mutation is rarer
than other mutations that enhance mtrCDE expression, it was
found in an additional multidrug-resistant strain that has been
included in the 2008 WHO N. gonorrhoeae reference strain panel
(15).
RESULTS
Analysis of the mtr120 locus in MS11 revealed that this C-to-T
transition creates the consensus sequence for a 10 element (TA
TAAT) (Fig. 1) (14). A near-consensus 35 element sequence
(TTGAGA) was located upstream of the potential 10 element;
however, this putative 35 hexamer was separated from the po-
tential 10 element by 24 bp rather than the optimal 17 bp (14).
Todetermineifthis10elementcouldacttopromotetranscrip-
tion, primer extension of mtrC was performed using total RNA
from FA19 and DW120 cultures at mid-log phase (Fig. 2). As
expected, primer extension of RNA from FA19 yielded a single
mtrC transcript, which mapped to the previously identiﬁed tran-
scription start site (Fig. 1) (1). The presence of the mtr120 muta-
tion, however, resulted in a second, shorter mtrC transcript that
wasmoreintensethanthewild-typemtrCtranscript,suggestinga
higher concentration of the shorter transcript. Importantly, the
start site for this second transcript mapped to a site 7 bp down-
stream of the 10 consensus sequence generated by mtr120, a rea-
sonable distance to suggest that this 10 sequence could act to
promote the expression of this transcript.
To rule out the possibility that the mutant transcript was a
result of differential mRNA processing due to the mtr120 muta-
tion,-galactosidaseassayswerecarriedoutwithFA19containing
a promoterless lacZ gene translationally fused to either the entire
mtrCpromoterregion(mtrCF-lacZ)oratruncatedregionlacking
the wild-type mtrC promoter (mtrCT-lacZ) (Fig. 3A) (16). The
FIG 1 The mtr locus in N. gonorrhoeae. (A) Organization of the mtr locus. Bent arrows mark the mtrR and mtrCDE promoters (P). mtrR and mtrCDE are
divergently transcribed on opposite strands. The locations of the mtr120 mutation and the mtrC-lacZ fusion start sites are indicated. The hatched box represents
thelocationoftheexpandedsequence.(B)SequenceofthemtrR-mtrCDEintergenicregion.ThepreviouslycharacterizedmtrRandmtrCDEpromoterelements,
the consensus 10 sequence generated by the mtr120 mutation, and the putative 35 element for the mtr120 promoter are indicated in the expanded sequence.
ThetranscriptionstartsitefromthepreviouslycharacterizedmtrCDEpromoterismarkedbyasinglecross;thetranscriptionstartpointfromthemtr120promoter
is marked by a double cross.
FIG 2 Primer extension analysis of mtrC from FA19 and DW120. Primer
extension products were generated using an mtrC-speciﬁc oligonucleotide
(Table 4) hybridized to 50 g of total RNA harvested from each strain. The
DNA sequence was produced using the same oligonucleotide and is comple-
mentarytothemRNA.Thewild-typeandmutantsequencesatthemtr120locus
are expanded, with the mutated nucleotide in bold.
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-galactosidase activity than the wild-type mtrCF-lacZ fusion. As
expected, the wild-type mtrCT-lacZ fusion showed no
-galactosidase activity. However, the mtr120 mtrCT-lacZ fusion
showed levels of -galactosidase activity signiﬁcantly higher than
those of the wild-type mtrCF-lacZ fusion, demonstrating that the
10 element generated by the mtr120 mutation is sufﬁcient for
transcription in the absence of the wild-type promoter and is
strongerthanthewild-typepromoter,inagreementwiththemore
intense band seen in the primer extension from mtr120. As further
veriﬁcation,wepreparedmtrC-lacZtranslationalfusionscontain-
ing a mutated 10 sequence (TATAAT to TGTCAC) of the wild-
type mtrCDE promoter (mtrCmut-lacZ). We observed that mtrC-
lacZ expression was abrogated when the wild-type promoter was
mutated and the sequence at position 120 was wild type (Fig. 3B).
However, mtrC-lacZ expression remained high when the mtr120
mutation was present. On the basis of these ﬁndings, we propose
thatthemtr120mutationdeﬁnesanewandhighlyactivepromoter
for mtrCDE transcription.
To characterize the resistance phenotype of the mtr120 muta-
tionanddetermineifMtrRandMtrA,theknownregulatorsofthe
mtrCDEwild-typepromoter,affecttheresistancelevelsconferred
by this mutation, we determined the MICs of antimicrobials
against strains FA19 and DW120 and mtrR and mtrA knockout
derivatives of each strain (genotypes described in Table 1, results
shown in Table 2). In agreement with the increased mRNA levels
detected in the primer extension experiment and high levels of
-galactosidase activity from the mtrC-lacZ fusions carrying the
mtr120 mutation, the presence of mtr120 resulted in increased re-
sistance to the MtrC-MtrD-MtrE pump substrates erythromycin
(Erm), rifampin (Rif), crystal violet (CV), and Triton X-100 (TX-
100).Incontrast,thepresenceofmtr120didnotaffectresistanceto
the nonpump substrate kanamycin (Km) in strains isogenic for
mtrR or mtrA; increased Km resistance in mtrR and mtrA knock-
out strains is due to the presence of the aphA-3 cassette within
these genes, and differences in resistance between strains with
mtrR disruption and mtrA disruption may be attributed to differ-
ences in promoter strength for these genes. Importantly, the ab-
senceofMtrRandMtrAdidnotaffectlevelsofresistancetopump
substrates in strains with mtr120, suggesting that, unlike the wild-
typepromoter(17),themtr120promoterisnotsubjecttoMtrRor
MtrA regulation.
To verify that the observed increased antimicrobial resistance
was due to increased levels of MtrC-MtrD-MtrE pump produc-
tion, Western blot analysis was conducted to determine the effect
of the mtr120 mutation on MtrE production. In agreement with
the results of the MIC assays, strains bearing the mtr120 mutation
producedmuchgreateramountsofMtrEthanstrainswithawild-
type sequence at this locus (Fig. 4). Additionally, the absence of
MtrR and MtrA did not appear to affect MtrE levels in the pres-
ence of mtr120, further suggesting that these regulators do not act
on the promoter generated by this mutation.
The mtr120 mutation was originally identiﬁed in strain MS11
(12),whichisacommonlyutilizedlaboratorystrainthathasbeen
usedingonococcalresearchformanyyears.Thus,todetermineif
the mtr120 mutation is present in strains isolated during recent
clinical infection, as well as to compare its frequency to other mtr
locus mutations in a clinical setting, the mtrR gene and the mtrR-
FIG 3 Expression of -galactosidase from the mtr120 locus. The
-galactosidaseactivitiespermilligramoftotalproteinincellextractsofFA19
containing translational mtrC-lacZ fusions are shown. Assays were performed
intriplicate.Errorbarsrepresent1standarddeviation.Asteriskscorrespondto
a P value of 0.01 (Student’s t test). (A) The mtr120 locus is sufﬁcient for
mtrC-lacZ expression in the absence of the wild-type (wt) promoter. (B) The
mtr120 locus promotes mtrC-lacZ expression when the wild-type mtrC pro-
moter is inactivated.
TABLE 1 Strains used in this study
Strain Relevant genotype Reference
FA19 Wild type 45
DW120 FA19 mtr120 12
KH9 FA19 mtrR::Kmr 7
CR1 FA19 mtrA::Kmr 8
EO1 FA19 mtr120 mtrR::Kmr This study
EO2 FA19 mtr120 mtrA::Kmr This study
RD1 mtrE::Kmr 44
TABLE 2 Sensitivity to substrates of the MtrC-MtrD-MtrE efﬂux
system
Strain Genotype
MIC (g/ml)
Erm Rif CV TX-100 Km
FA19 Wild type 0.25 0.06 0.6 125 30
KH9 FA19 mtrR::Kmr 1 0.12 1.25 250 480
CR1 FA19 mtrA::Kmr 0.25 0.06 0.6 125 240
DW120 FA19 mtr120 2 0.25 2.5 16,000 30
EO1 FA19 mtr120 mtrR::Kmr 2 0.25 2.5 16,000 480
EO2 FA19 mtr120 mtrA::Kmr 2 0.25 2.5 16,000 240
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encestrainswereselectedonthebasisoftheirazithromycinMICs
and sequenced. The azithromycin MIC range for the N. gonor-
rhoeae isolates sequenced, including the eight 2008 WHO refer-
ence strains (15), was 0.125 to 8 g/ml, with 76% of the strains
foundtoberesistanttoazithromycinbytheEuropeanCommittee
on Antimicrobial Susceptibility Testing (EUCAST; http://www
.eucast.org) standard (MIC, 0.5 g/ml). Among these strains,
onlyone,the2008WHOreferencestrainWHOL(15),wasfound
tocontainthemtr120mutation.Thisstrainwasalsofoundtocon-
tain the previously described G45D mutation in the HTH DNA-
binding domain of MtrR (11). In contrast to the low frequency of
the mtr120 mutation, the previously deﬁned single nucleotide (A)
deletioninthe13-bpinvertedrepeatlocatedbetweenthe10and
35 sequences of the mtrR promoter was found in 86 isolates
(71%), of which 8 (7%) also had the G45D amino acid alteration
in the coding region of mtrR (7). Moreover, ﬁve additional muta-
tions in the promoter region of mtrR were found in a total of 12
isolates. Alteration of G45 (G45D [n  11] and G45S [n  3]) in
the mtrR coding region alone was present in 14 isolates (12%).
Other frequently occurring amino acid alterations found in the
codingregionofmtrRwereA86T,whichwasfoundin109isolates
(90%); Y105H, which was found in 25 isolates (21%); D79N,
which was found in 9 isolates (7%); A39T, which was found in 7
isolates (6%); and L99G/H, which was found in 3 isolates (2%)
(Table 3).
DISCUSSION
The mtr120 mutation is novel in its mechanism of providing anti-
microbialresistanceinthatitcreatesanentirelynewpromoterfor
mtrCDE transcription and acts independently of the MtrR and
MtrA transcription regulatory proteins. To our knowledge, this is
the ﬁrst report of such a mechanism of efﬂux pump regulation.
Two precedents exist in N. gonorrhoeae, however, for the upregu-
lation of efﬂux pumps through cis-acting point mutations at ex-
isting promoters. First, the expression of norM, a gene encoding a
multidrug and toxic compound extrusion family exporter that
contributes to quaternary ammonium compound, norﬂoxacin,
andciproﬂoxacinresistance,isupregulatedbypointmutationsin
the 35 hexamer (C to T) of the norM promoter or in the
ribosome-binding site (A to G) (5). Second, a point mutation in
the 10 hexamer (G to T) of the promoter for macAB, which
encodes an ABC transporter family efﬂux system that contributes
to macrolide resistance, results in the increased expression of this
efﬂux pump (4). Like the mtr120 mutation, these point mutations
bring their respective promoter elements closer to the consensus
sequences (TTGACA for the 35 element; AGGAGG for the
ribosome-binding site), thereby enhancing recognition by RNA
polymerase or, in the case of norM, the ribosome (14, 18). The
mtr120 mutation is novel, however, in that there is no expression
from the wild-type sequence at this locus, and the consensus 10
element generated by the mtr120 mutation acts as a second, inde-
pendent promoter for mtrCDE transcription.
The mtr120 mutation appears to offer the gonococcus a rela-
tively simple and convenient mechanism of antibiotic resistance.
The change of this single base pair signiﬁcantly increases mtrCDE
FIG 4 Expression of MtrE by wild-type and mtr120 mutant strains. Western
blot analysis of whole-cell lysates from late-log-phase cultures was conducted
using polyclonal rabbit MtrE-speciﬁc antibodies, followed by goat anti-rabbit
IgG-alkaline phosphatase. Strain RD1 (44) contains a Kmr insertion in mtrE
and was used as a negative control. The total protein from all strains was
equallyloaded,asassessedbyCoomassiebluestainingofaseparateSDS-PAGE
gel (data not shown).
TABLE 3 The MIC of azithromycin and frequency of recovery of mutations in the promoter region of mtrR and the coding region of mtrR and the
mtr120 mutation in 113 N. gonorrhoeae clinical isolates from 2002 to 2009 and 8 WHO N. gonorrhoeae reference strains from 2008
Azithromycin MIC (g/ml) (no. of isolates)
No. of isolates with:
mtrR promoter mutation Nonsynonymous mutation in mtrR coding region
mtr120 Aa C¡Ab Tc Gd Te A¡Cf G45D/G45S A86T Y105H D79N A39T L99G/L99H
0.125 (2) 1
0.25 (4) 4 2 4
0.38 (14) 7 3 2 9 2 5 2 2
0.5 (9) 4 2 1 7 2 2 1 1 1
0.75 (43) 34 1 1 2 10 41 12 1 2
1 (30) 26 1 3 29 3 1 2
1.5 (8) 7 1 8 1
2 (4) 2 1 1 4 1
4 (2) 2 2
6 (4) 1 3 3 3
8 (1) 11 1
Total (121) 86 6 2 1 2 1 24 109 25 9 7 3 1
a Deletion of A in 13-bp inverted repeat in the mtrR promoter.
b Transversion from C to A 19 nucleotides upstream of where the A deletion occurs.
c Insertion of one T 10 nucleotides downstream of where the A deletion occurs.
d Deletion of one G 34 nucleotides upstream of where the A deletion occurs.
e Deletion of one T 21 nucleotides upstream of where the A deletion occurs.
f Transversion from A to C in the inverted repeat 3 nucleotides upstream of where the A deletion occurs.
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out disrupting other components of the efﬂux system, including
the regulators MtrR and MtrA. Both MtrR and MtrA are global
regulatorsinN.gonorrhoeae,controllingamultitudeofgenesout-
side the mtrCDE operon, many of which are important for viru-
lence and in vivo ﬁtness (19, 20). Thus, the ability to upregulate
mtrCDEwithoutaffectingtheregulationofothergenesneededfor
infection and survival would be a highly efﬁcient and minimally
disruptivemechanismofdevelopingantimicrobialresistance.Itis
therefore somewhat surprising that this mutation is so rare, espe-
cially compared to the frequency of mtrR promoter and coding
region mutations in the clinical isolates examined in this study.
Thereasonfortherarityofthemtr120mutationisthusamatter
of speculation. The production of efﬂux pumps is an energy-
expensive process, and it is therefore possible that the high levels
of MtrC-MtrD-MtrE production stimulated by this mutation
stress the gonococcus, resulting in slower or defective growth. In
this respect, Eisenstein and Sparling noted that a single base pair
deletion in the inverted repeat in the mtrR promoter, a mutation
which also confers high-level antibiotic resistance through in-
creased transcription of mtrCDE, results in a lower growth rate in
vitro(7,21).However,unlikemtr120,thismutationwasrecovered
with high frequency in the strains sequenced in this study, and
withthemorerecentﬁndingthatMtrRactsasaglobalregulatorin
the gonococcus, it is possible that the observed growth defect was
at least in part due to lack of mtrR expression. Additionally, we
havenoticednodifferenceintheinvitrogrowthkineticsofstrains
carrying mtr120 and strains wild type at this site (data not shown),
andWarneretal.foundthatstrainDW120hasaﬁtnessadvantage
in vivo over FA19 in a female mouse model of lower genital tract
infection (12).
Anotherpossibilitytoexplaintherarityofthemtr120mutation
is that the mutational event required for this change occurs less
frequently than those required for other mutations, particularly
thedeletionintheinvertedrepeat.Aspeciﬁcnucleotidechangeat
a single base pair locus is required to generate the mtr120 pheno-
type. However, one of any ﬁve base pairs may be deleted in the
invertedrepeattocausehigh-levelresistance.Thus,itmaybethat
the mtr120 mutation is simply less likely to occur, which would
account for its scarcity in the isolates sequenced. Further analysis
of the mtr120 mutation and its overall effects is required to eluci-
date the reason for this mutation’s relative infrequency.
It is important to note that the mtr120 mutation was originally
identiﬁed in strain MS11 (12). This strain has been used exten-
sively in the laboratory for studies on neisserial pili (22–25), Opa
proteins (26, 27), in vitro cell infection (28, 29), antimicrobial
resistance (30), and in vivo pathogenesis in male volunteers (31–
34). The possession of this rare mutation, however, makes MS11
uncommon compared to other gonococcal strains, enhancing its
resistance not only to antibiotics but also to host antimicrobial
compoundsthatareMtrC-MtrD-MtrEsubstrates,suchasthean-
timicrobial peptide LL-37 (6). MS11 has been found to be more
infectious than another commonly studied N. gonorrhoeae strain,
FA1090, in experimental infection of male volunteers (35), and it
is likely that increased resistance to host antimicrobial com-
poundsduetothemtr120mutationplaysanimportantroleinthis
increasedinfectivity.Itisthereforeimportanttoconsiderthismu-
tation when interpreting ﬁndings from previous studies using
strain MS11, particularly those involving antimicrobial resistance
andpathogenesisandhumanvolunteerstudiesinwhichvirulence
factors important in the evasion of innate defenses were assessed
(35).
ItisalsoimportanttonotethatWHOreferencestrainWHOL
carries the mtr120 mutation. Although its levels of resistance to
Ermandazithromycinwerefoundtobeslightlyhigherthanthose
ofreferencestrainswiththesinglenucleotidedeletioninthe13-bp
inverted repeat of the mtrR promoter, WHO L does not contain
this deletion, and its resistance was thus considered to be attrib-
utable to the G45D mutation in the HTH domain of MtrR (15).
However, as mutations in the HTH domain of MtrR generally
confer only low levels of antimicrobial resistance, it is far more
likelythatthehigherlevelofazithromycinresistanceofWHOLis
due to the presence of mtr120, which is an important factor to
consider in its use as a reference strain.
Thisstudydemonstratesthesigniﬁcantimpactsinglebasepair
mutations may have on gene expression and the development of
antimicrobial resistance and characterizes a novel cis-regulatory
mechanism for efﬂux pump expression. Sequence analysis of the
promoter regions of other efﬂux pumps, both in Neisseria and in
other pathogenic organisms, will determine if this mechanism is
widely used among pathogens or is unique to N. gonorrhoeae and
mtrCDE.Additionally,themtr120mutationprovidesauniqueop-
portunity for study of the physiological consequences of efﬂux
pump overexpression on bacterial cells. This single point muta-
tion in a noncoding region allows overproduction of the MtrC-
MtrD-MtrEefﬂuxpumpwithoutdisruptionoralteredexpression
of local or global regulatory proteins. Thus, the direct phenotypic
consequencesofhigh-levelefﬂuxpumpproductioncanbeexam-
inedwithouttheintroductionofconfoundingeffectsoncellphys-
iology due to altered regulation of other genes, a challenge which
has been difﬁcult to overcome. Further study of the mtr120 muta-
tion will help advance our understanding of antimicrobial resis-
tance mechanisms, as well as elucidate the physiological conse-
quences of efﬂux pump overexpression on bacterial cells.
MATERIALS AND METHODS
Bacterialstrainsandcultureconditions.Gonococciwereroutinelygrown
on GCB agar (Difco Laboratories, Detroit, MI) containing deﬁned supple-
ments I and II (36) at 37°C under 4% CO2 or in GCB broth (Difco Labora-
tories, Detroit, MI) containing deﬁned supplements I and II and 0.048%
(vol/vol) sodium bicarbonate with shaking at 37°C. E. coli DH5 was rou-
tinely grown on LB agar or in LB broth (Difco Laboratories, Detroit, MI).
The N. gonorrhoeae strains used in this study are described in Table 1.
The oligonucleotide primers used are listed in Table 4. Strains DW120,
KH9, and CR1 were previously described (1, 8, 12). Strain EO1 was con-
structedbytransformationofDW120withthemtrR::KmrgenefromKH9
chromosomalDNAbyPCRampliﬁcationusingprimersKH9#10B,which
anneals 10 bp downstream of the mtrR translational start site, and CEL1,
which anneals 120 bp downstream of the mtrR translational stop site (1).
Strain EO2 was constructed by transformation of DW120 with themtrA::
Kmr gene from CR1 PCR ampliﬁed using primers C6, which anneals
255bpupstreamofthemtrAtranslationalstopsite,andC7,whichanneals
232bpdownstreamofthemtrAtranslationalstartsite.PCRproductswere
puriﬁed using the QIAquick PCR puriﬁcation kit (Qiagen Inc., Valencia,
CA). Puriﬁed products were transformed into FA19, and transformants
were selected on GCB agar supplemented with 50 g/ml Km. Transfor-
mations were performed as previously described (37). All transformants
were conﬁrmed by PCR.
Primer extension of mtrC. Total RNA was prepared from gonococci
by the method of Baker and Yanofsky (38). Primer extension analysis of
mtrC was performed using SuperScript II reverse transcriptase (Invitro-
gen Co., Carlsbad, CA) according to the manufacturer’s instructions.
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labeled oligonucleotide primer PEmtrC181, which anneals to the ﬁrst
seven codons of mtrC (Table 4). To determine transcription start sites,
primer extension products were electrophoresed on a 6% sequencing gel
alongside reference sequencing reaction products derived from the
PEmtrC181 primer using an mtrCDE promoter region PCR product am-
pliﬁed using primers mtrC_F and mtrC_R as templates. Sequencing was
performedusingtheSequiThermEXCELIIDNAsequencingkit(Epicen-
ter Biotechnologies, Madison, WI) by following the manufacturer’s in-
structions. The dried gel was exposed to Kodak XAR ﬁlm overnight at
70°C and developed using a Kodak X-Omat 1000A ﬁlm processor.
Construction of mtrC-lacZ fusions. Translational lacZ fusions were
constructed as previously described (16). Brieﬂy, the mtrC promoter re-
gion from FA19 or DW120 was ampliﬁed using primers that introduce a
BamHI restriction site at the end of the PCR products; primer sequences
are listed in Table 4. For all fusions, mtrC_7, which anneals to the ﬁrst six
codons of mtrC, was used as the reverse primer. Forward primer mtrC_3
was used to amplify the mtrC promoter sequence beginning 239 bp up-
stream of the mtrC start codon, encompassing all mtrC promoter ele-
ments,tomakefusionswild-typemtrCF-lacZandmtr120mtrCF-lacZ.For-
ward primer mtrC_4 was used to PCR amplify a region beginning 157 bp
upstream of the mtrC start codon from FA19 or DW120, excluding the
previously identiﬁed mtrC promoter and transcription start site (1), to
make the wild-type mtrCT-lacZ and mtr120 mtrCT-lacZ fusions. Forward
primer PmtrCmut was used to PCR amplify a region beginning 254 bp
upstream of the mtrC start codon from FA19 or DW120 and mutate the
10 region of the wild-type mtrC promoter from TATAAT to TGTCAC.
PCR products were digested with BamHI, and the resulting DNA frag-
ments were inserted into the BamHI site of pLES94 (16). Recombinant
plasmids were transformed into E. coli DH5. Transformants were se-
lected on LB agar containing 100 g/ml ampicillin. Correct insertion and
orientation were conﬁrmed by PCR analysis and DNA sequencing. The
plasmidsweretransformedintoFA19toallowinsertionintothechromo-
somalproABlocus.TransformantswereselectedonGCBagarcontaining
1 g/ml chloramphenicol.
Preparationofcellextractsand-galactosidaseassays.Strainscon-
taining translational mtrC-lacZ fusions were grown overnight on GCB
agar plates containing 1 g/ml chloramphenicol. Cells were scraped,
washed once with phosphate-buffered saline (pH 7.4), and resuspended
in lysis buffer (24 mM Na2HPO4,1 6m MN a H 2PO4, 4 mM KCl, 0.4 mM
MgSO4 ·7 H 2O). Cells were lysed by repeated freeze-thaw cycles, and cell
debris was removed by centrifugation at 9,300  g for 10 min at 4°C.
-Galactosidase assays were performed as previously described (39).
MIC assays. The MICs of Erm, Rif, CV, TX-100, and Km were deter-
minedby2-foldagardilutionassay(36).StrainsweregrownonGCBagar
andresuspendedinGCBbrothtoanopticaldensityat600nmof0.1,and
5-l samples of these suspensions were inoculated onto GCB agar plates
containing 2-fold serial dilutions of antibiotics. Plates were incubated
TABLE 4 Oligonucleotide primers used in this study
Name Sequence Purpose
KH9#10B 5= CCAAAACCGAAGCCTTGAAAACCAA 3= mtrR::Kmr
ampliﬁcation
CEL1 5= GACAATGTTCATGCGATGATAGG 3= mtrR::Kmr
ampliﬁcation
C6 5= CGACATTCCATTCGTCTTCCGG 3= mtrA::Kmr
ampliﬁcation
C7 5= GCCACGACGGAAAATGCGGAG 3= mtrA::Kmr
ampliﬁcation
PEmtrC181 5= CCTTAGAAGCATAAAAAGCCAT 3= Primer
extension
of mtrC
mtrC_3 5= AGTCGGATCCGGTTTGACGAGGGCGGAT 3= Full
mtrC-lacZ
fusion
mtrC_4 5= AGTCGGATCCAATTGAGACTGCATCT CAACT 3= Truncated
mtrC-lacZ
fusion
PmtrCmut 5= AGTGGATCCGTTTCGGGTCGGTTTGACGAGGG
CGGATTATAAAAAAGACTTTTTATCCGTGCAA
TCGTGTATGTAGCACGAAACCCA 3=
Wild-type
mtrC
promoter 10 mutation
for lacZ
fusion
mtrC_7 5= AGTCGGATCCGAAGCATAAAAAGCC 3= Reverse
mtrC promoter
primer
mtrC_F 5= CGTTTCGGGTCGGTTTGACG 3= mtrR-mtrC
intergenic
region
ampliﬁcation
mtrC_R 5= CATCGCCTTAGAAGCATAAAAAGCC 3= mtrR-mtrC
intergenic
region
ampliﬁcation
MTR1 5= AACAGGCATTCTTATTTCAG 3= mtrR
ampliﬁcation
MTR2 5= TTAGAAGAATGCTTTGTGTC 3= mtrR
ampliﬁcation
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2-fold were considered signiﬁcant.
Western blot analysis of MtrE expression. Whole-cell lysates from
late-log-phase cultures (approximately 108 cells per sample) were sub-
jected to 10% SDS-PAGE and transferred to nitrocellulose. The mem-
branewasprobedwitha1:10,000dilutionofrabbitpolyclonalantibodies
against amino acids 110 to 120 of MtrE (RQGSLSGGNVS) (20). Detec-
tion was performed with a 1:10,000 dilution of goat anti-rabbit IgG sec-
ondary antibody conjugated to alkaline phosphatase (Bio-Rad Laborato-
ries, Hercules, CA) exposed to 5-bromo-4-chloro-3-indolylphosphate
(BCIP) and Nitro Blue Tetrazolium (Roche Applied Science, Indianapo-
lis, IN) according to the manufacturer’s instructions.
Detection of the mtr120 mutation in clinical isolates. All examined
clinical N. gonorrhoeae isolates (n  113) were obtained at the National
Reference Laboratory for Pathogenic Neisseria, Örebro University Hos-
pital, Örebro, Sweden, from 2002 through 2009. Isolates were cultured
frompatientsexposedtoinfectioninmanycountriesworldwideandwere
includedbasedonhavinganazithromycinMICof0.38g/ml.Further-
more, the 2008 WHO N. gonorrhoeae reference strains (n  8) were in-
cluded for examination and quality control in all assays (15). The identi-
ties of all isolates were conﬁrmed to the species level by the sugar
utilization test and/or the Phadebact GC Monoclonal Test (Boule Diag-
nostics AB, Huddinge, Sweden), and they were preserved as previously
described (40).
The MIC (g/ml) of azithromycin was determined using the Etest
method (AB bioMérieux, Solna, Sweden) as previously described (41).
The breakpoints used for susceptibility, intermediate susceptibility, and
resistance were according to EUCAST; for azithromycin, susceptibility
was 0.25 g/ml and resistance was 0.5 g/ml.
N. gonorrhoeae DNA was isolated in the NorDiag Bullet instrument
(Nordiag ASA Company, Oslo, Norway) using the BUGS’n BEADS STI-
fast kit (Nordiag ASA Company), according to the manufacturer’s in-
structions.Toidentifyputativemutationsthatcauseenhancedexpression
of the MtrC-MtrD-MtrE efﬂux pump, the mtrR-mtrC intergenic region
was ampliﬁed in a LightCycler 1.2 real-time PCR system (Roche Molecu-
lar Biochemicals, Mannheim, Germany) using primers mtrC_F, which
anneals 11 bp upstream of the mtrR start codon and 249 bp upstream of
the mtrC start codon (17), and mtrC_R, which anneals 24 nucleotides
downstream of the mtrC translational start (1). Additionally, the pro-
moterandcodingregionofmtrRwasampliﬁedusingprimersMTR1and
MTR2 (42) as previously described (43). All PCR ampliﬁcation products
were puriﬁed prior to sequencing using the High Pure PCR Product Pu-
riﬁcation Kit (Roche Diagnostics GmbH, Mannheim, Germany). Both
DNA strands of amplicons were sequenced using the same primers as in
thePCRampliﬁcationdescribedaboveusingtheBigDyeTerminatorv3.1
Cycle Sequencing Kit (Applied Biosystems, Foster City, CA) on an ABI
3120 Genetic Analyzer (Applied Biosystems) according to the manufac-
turer’s instructions. Nucleotide and amino acid multiple-sequence align-
ments were performed using the BioEdit (version 5.0.9) software.
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